| Pelvic inflammatory disease. Key treatment issues and options. | |
| | |
MedLine Citation:
|
PMID: 1658404 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE:--To examine available data regarding optimal antimicrobial therapy for pelvic inflammatory disease (PID) and to address selected treatment issues confronting clinicians caring for women with PID. DATA SOURCES:--Studies evaluated to help establish the Centers for Disease Control's 1989 Sexually Transmitted Diseases Treatment Guidelines and other reports published since 1985. A MEDLINE search of English-language literature was conducted using the indexing terms "pelvic inflammatory disease" or "pelvic infections" or "salpingitis" and "treatment". In addition, abstracts and bibliographies of articles and books were reviewed. STUDY SELECTION:--Studies were selected for detailed review if they evaluated the effectiveness of an antimicrobial regimen for treatment of PID. DATA EXTRACTION:--All studies were evaluated to determine the numbers of women treated and the percentage with clinical or microbiologic evidence of cure. DATA SYNTHESIS:--A variety of combination antimicrobial regimens are highly effective in providing clinical and microbiologic evidence of cure; few data are available to assess optimal therapy for prevention of late sequelae. Because PID is polymicrobial in cause, recommended antimicrobial regimens are broad-spectrum in coverage. CONCLUSIONS:--No single agent that provides sufficient coverage is currently available. Several combination regimens appear highly effective clinically even among women with tubo-ovarian abscess formation. Uncertainties regarding the effectiveness of antimicrobial therapy for prevention of late sequelae complicate decisions regarding the choice among regimens and the appropriateness of ambulatory treatment of women with PID. Pending better data, hospitalization should be strongly considered, where feasible, particularly for those women with PID desiring further childbearing. Sex partners of all women with PID should be treated. |
| | |
Authors:
|
H B Peterson; C K Walker; J G Kahn; A E Washington; D A Eschenbach; S Faro |
Related Documents
:
|
17012514 - Sti declines among sex workers and clients following outreach, one time presumptive tre... 707474 - Cohort study of venereal disease. i: the risk of gonorrhea transmission from infected w... 10023354 - Validation of the who diagnostic algorithm and development of an alternative scoring sy... 18562984 - Reproductive tract complications associated with chlamydia trachomatis infection in us ... 9120514 - Prevalence and determinants of coronary heart disease in a rural population of india. 22311294 - Urinary 11-dehydro-thromboxane b(2) and 2,3-dinor-6-keto-prostaglandin-f(1α) in health... |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S.; Review |
Journal Detail:
|
Title: JAMA : the journal of the American Medical Association Volume: 266 ISSN: 0098-7484 ISO Abbreviation: JAMA Publication Date: 1991 Nov |
Date Detail:
|
Created Date: 1991-11-29 Completed Date: 1991-11-29 Revised Date: 2010-03-24 |
Medline Journal Info:
|
Nlm Unique ID: 7501160 Medline TA: JAMA Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 2605-11 Citation Subset: AIM; IM |
Affiliation:
|
Division of Reproductive Health, Centers for Disease Control, Atlanta, GA 30333. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Bacterial Agents* Centers for Disease Control and Prevention (U.S.) Chlamydia Infections / drug therapy* Chlamydia trachomatis* Clinical Protocols Clinical Trials as Topic Drug Therapy, Combination / therapeutic use* Female Gonorrhea / drug therapy* Humans Pelvic Inflammatory Disease / drug therapy* Treatment Outcome United States |
| Grant Support | |
ID/Acronym/Agency:
|
282-88-0018//PHS HHS; AI24768/AI/NIAID NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents |
| Comments/Corrections | |
Comment In:
|
JAMA. 1991 Nov 13;266(18):2612
[PMID:
1942406
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intravenous recombinant soluble human thrombomodulin prevents venous thrombosis in a rat model.
Next Document: Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin.